← Arcus Biosciences, Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $0 $1.4m $8.4m $15.0m $77.5m $382.9m $112.0m $117.0m $51.0m $33.0m
Research and development (Includes $25, ($39) and ($110) payments to/(from) a related party) $14.2m $47.2m $49.6m $78.5m $159.3m $256.3m $288.0m $340.0m $448.0m $523.0m
Research And Development $14.2m $47.2m $49.6m $78.5m $159.3m $256.3m $288.0m $340.0m $448.0m $523.0m
Operating Expenses $18.2m $54.9m $63.2m $103.7m $201.8m $328.6m $392.0m $457.0m $588.0m $633.0m
Total operating expenses $18.2m $54.9m $63.2m $103.7m $201.8m $328.6m $392.0m $457.0m $588.0m $633.0m
Operating Income (Loss) ($18.2m) ($53.4m) ($54.9m) ($88.7m) ($124.2m) $54.2m ($280.0m) ($340.0m) ($330.0m) ($386.0m)
Additional Financial Items
Income (Loss) from Continuing Operations before Income Taxes, Domestic — — — — — $53.9m ($267.0m) ($301.0m) ($283.0m) ($353.0m)
Income (Loss) from Continuing Operations, Per Basic Share — — — — — $1 ($4) ($4) — —
Income (Loss) from Continuing Operations, Per Diluted Share — — — — — $1 ($4) ($4) — —
Income (Loss) from Equity Method Investments — ($416k) ($886k) ($1.2m) ($613k) — — — — —
General and administrative (Includes $5, $2 and $— payments to a related party) $3.9m $7.6m $13.6m $25.2m $42.4m $72.3m $104.0m $117.0m $120.0m $110.0m
Impairment of long-lived assets (see Note 14, Leases) — — — — — — $0 $0 $20.0m $0
Loss from operations ($18.2m) ($53.4m) ($54.9m) ($88.7m) ($124.2m) $54.2m ($280.0m) ($340.0m) ($330.0m) ($386.0m)
Interest and other income, net $212k $775k $4.9m $5.2m $1.4m $657k $16.0m $41.0m $52.0m $41.0m
Loss before income taxes — — — ($84.7m) ($122.9m) $54.6m ($266.0m) ($301.0m) ($282.0m) ($353.0m)
Net loss ($18.0m) ($53.1m) ($49.6m) ($84.7m) ($122.9m) $52.8m ($267.0m) ($307.0m) ($283.0m) ($353.0m)
Diluted EPS — — — — — $0.76 ($3.71) ($4.15) ($3.14) ($3.29)
Diluted NI Availto Com Stockholders ($18.0m) ($53.1m) ($49.6m) ($84.7m) ($122.9m) $52.8m ($267.0m) ($307.0m) ($283.0m) ($353.0m)
Impairment Of Capital Assets — — — — — — $0 $0 $20.0m $0
Interest Income $212k $775k $4.9m $5.2m $1.4m $657k $16.0m $41.0m $52.0m $41.0m
Interest Income Non Operating $212k $775k $4.9m $5.2m $1.4m $657k $16.0m $41.0m $52.0m $41.0m
Net Income From Continuing And Discontinued Operation ($18.0m) ($53.1m) ($49.6m) ($84.7m) ($122.9m) $52.8m ($267.0m) ($307.0m) ($283.0m) ($353.0m)
Net Income From Continuing Operation Net Minority Interest ($18.0m) ($53.1m) ($49.6m) ($84.7m) ($122.9m) $52.8m ($267.0m) ($307.0m) ($283.0m) ($353.0m)
Net Interest Income $212k $359k $5.3m $4.0m $1.4m $397k $14.0m $39.0m $48.0m $33.0m
Normalized EBITDA — — — — — — ($258.0m) ($291.0m) ($248.0m) ($335.0m)
Normalized Income — — — — — — ($267.0m) ($307.0m) ($267.2m) ($353.0m)
Other Gand A $3.9m $7.6m $13.6m $25.2m $42.4m $72.3m $104.0m $117.0m $120.0m $110.0m
Reconciled Depreciation — — — — — — $6.0m $8.0m $10.0m $10.0m
Selling General And Administration $3.9m $7.6m $13.6m $25.2m $42.4m $72.3m $104.0m $117.0m $120.0m $110.0m
Special Income Charges — — — — — — $0 $0 ($20.0m) $0
Tax Effect Of Unusual Items — — — — — — $0 $0 ($4.2m) $0
Tax Provision — — — — — $1.8m $1.0m $6.0m $1.0m $0
Tax Rate For Calcs — — — — — — $0 $0 $0 $0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest — — — ($84.7m) ($122.9m) $54.6m ($266.0m) ($301.0m) ($282.0m) ($353.0m)
Total non-operating income, net $212k $359k $5.3m $4.0m $1.4m $397k $14.0m $39.0m $48.0m $33.0m
Total Unusual Items — — — — — — $0 $0 ($20.0m) $0
Total Unusual Items Excluding Goodwill — — — — — — $0 $0 ($20.0m) $0
Pre-Tax Income — — — ($84.7m) ($122.9m) $54.6m ($266.0m) ($301.0m) ($282.0m) ($353.0m)
Net Income Continuous Operations ($18.0m) ($53.1m) ($49.6m) ($84.7m) ($122.9m) $52.8m ($267.0m) ($307.0m) ($283.0m) ($353.0m)
Net Income (Loss) Attributable to Parent ($18.0m) ($53.1m) ($49.6m) ($84.7m) ($122.9m) $52.8m ($267.0m) ($307.0m) ($283.0m) ($353.0m)
Net Income Including Noncontrolling Interests ($18.0m) ($53.1m) ($49.6m) ($84.7m) ($122.9m) $52.8m ($267.0m) ($307.0m) ($283.0m) ($353.0m)
Earnings Per Share, Basic — — — — — $0.76 ($3.71) ($4.15) ($3.14) ($3.29)
Earnings Per Share, Diluted — — — — — $0.71 ($3.71) ($4.15) ($3.14) ($3.29)
Weighted Average Number of Shares Outstanding, Basic — 3.9m 36.4m 45.4m — 69.3m 72.0m 74.0m 90.1m 107.4m
Basic Average Shares — 3.9m 36.4m 45.4m — 69.3m $72.0m $74.0m $90.1m $107.4m
Diluted Average Shares — 3.9m 36.4m 45.4m — 69.3m $72.0m $74.0m $90.1m $107.4m
Weighted Average Number of Shares Outstanding, Diluted — — — — — 74.0m 72.0m 74.0m 90.1m 107.4m
Research and Development Expense $14.2m $47.2m $49.6m $78.5m $159.3m $256.3m $288.0m $340.0m $448.0m $523.0m
General and Administrative Expense $3.9m $7.6m $13.6m $25.2m $42.4m $72.3m $104.0m $117.0m $120.0m $110.0m
Interest Expense (non-operating) — — — — — — $2.0m $2.0m $4.0m $8.0m
Interest Expense, Debt — — — — — — — — $2.0m $9.0m
Interest expense — — — — — — ($2.0m) ($2.0m) ($4.0m) ($8.0m)
Income tax expense — — — — — ($1.8m) ($1.0m) ($6.0m) ($1.0m) $0
Net Non Operating Interest Income Expense $212k $359k $5.3m $4.0m $1.4m $397k $14.0m $39.0m $48.0m $33.0m
Operating Expense — — — — — — $392.0m $457.0m $568.0m $633.0m
Income Tax Expense (Benefit) — — — — — $1.8m $1.0m $6.0m $1.0m $0
Total Expenses — — — — — — $392.0m $457.0m $568.0m $633.0m

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.